Bibliography
- Frew AJ. Sublingual Immunotherapy. N Engl J Med 2008;358:21
- Passalacqua G, Durham SR. Allergic Rhinitis and its Impact on Asthma update: Allergen immunotherapy. J Allergy Clin Immunol 2007;119:881-91
- Patel P, Salapatek AM. Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine. Expert Rev Vaccines 2006;5(5):617-29
- Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2008;3
- Cox L, Linneman DL, Nolte H, et al. Sublingual immunotherapy: A comprehensive review. J Allergy Clin Immunol 2006;117:1021-35
- Pajno G. Sublingual immunotherapy: the optimism and the issues. J Allergy Clin Immunol 2007;119:797
- Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338-45
- McCormick P, Wagstaff A. Ultra-Short-Course Seasonal Allergy Vaccine (Pollinex Quattro). Drugs 2006;66(7):931-8
- Puggioni F, Durham SR, Francis JN. Monophosphryl Lipid A (MPL) promotes allergen-induced immune deviation in favour of TH1 responses. Allergy 2005;60:678-84
- Hopkins M, Lees BG, Richardson DG, et al. Standardization of Glutaraldehyde-modified Tyrosine-adsorbed Tree Pollen Vaccines Containing the Th1-inducing Adjuvant, Monophosphoryl Lipid A (MPL). Allergol et Immunopathol 2001;29(6):245-54
- Stuck B, Schneider-Gene S, Schafer D, et al. Short-Term Preseasonal Immunotherapy with Birch Pollen Allergoid Plus Mono-phosphoryllipid A (MPL). Allergy Clin Immunol Int J World Allergy Org 2004;16(2):60-4
- Rover AC, Reimann S, Zuberier T, et al. Immunophenotypic characterization of peripheral B cells. During short-term immunotherapy with tree pollen allergoid and the immunoadjuvant monophosphoryl lipid A. J Investig Allergol Clin Immunol 2002;12(4):227-34
- Drachenberg KJ, Wheeler AW, Stuebner P, et al. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001;56:498-505
- Drachenberg KJ, Heinzkill M, Urban E. Short-term immunotherapy with tree pollen allergoids and the adjuvant monophosphoryl lipid A: results from a multicentre, placebo-controlled, randomized, double-blind study. Allergologie 2002;25(9):446-74
- Drachenberg KJ, Heinzkill M, Urban E, et al. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents. Allergol et Immunopathol 2003;31(5):270-7
- Chudak M, Patel P, Salapatek A, et al. Tree Pollen Allergoids in Pollinex Quattro Tree Immuno-therapy Reduce the Residual Allergenicity as Assessed with Skin Prick Test (SPTs). J Allergy Clin Immunol 119(1):S57
- Drachenberg KJ, Proll S, Urban E, et al. Short-term immunotherapy using an allergy vaccine adjuvanted with monophosphoryl lipid A: a post-marketing surveillance study. Int Rev Allergol Clin Immunol 2002;8(4):219-23
- Bousquet J, Lockey R, Malling HJ, et al. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. J Allergy Clin Immunol 1998;102:558-62